

REMARKS

This response is being submitted within the shortened two-month statutory period set for responding to the October 1, 2001 document entitled "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)." (A copy of the document entitled "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)" is enclosed herewith for the Examiner's convenience.) Therefore, a fee for an extension of time is not required.


In response to the October 1, 2001 document entitled "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)," we are enclosing herewith a document entitled "Sequence Listing," which is a formal sequence listing. A copy of the "Sequence Listing" is included on the enclosed computer-readable diskette. Also enclosed herewith is a document entitled "Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821-1.825," which indicates that the formal written "Sequence Listing" does not include new matter and that the information recorded on the computer-readable diskette is identical to the formal written "Sequence Listing."

The enclosed formal written "Sequence Listing" numbers five sequences (SEQ ID NOS:1-5) that was not previously numbered in the originally filed U.S. patent application. Therefore, this response amends the fourth paragraph on page 18 of the specification to identify SEQ ID NO:1; this response amends the first paragraph on page 25 of the specification to identify SEQ ID NO:2 and SEQ ID NO:3; and this respond amends the first paragraph on page 29 of the specification to identify SEQ ID NO:4 and SEQ ID NO:5.

November 30, 2001

The Commissioner is authorized to charge any additional fees which may be required or credit overpayment to Deposit Account No. 12-0415. In particular, if this response is not timely filed, then the Commissioner is authorized to treat this response as including a petition to extend the time period pursuant to 37 C.F.R § 1.136(a) requesting an extension of time of the number of months necessary to make this response timely filed; and the petition fee due in connection therewith may be charged to deposit account No. 12-0415.

Respectfully submitted,



John Palmer  
Attorney for the Applicant  
Registration No.: 36,885  
LADAS & PARRY  
5670 Wilshire Boulevard, Suite 2100  
Los Angeles, California 90036-5679  
Telephone No.: (323) 934-2300  
Facsimile No.: (323) 934-0202

Enclosures: A copy of the October 1, 2001 document entitled  
"NOTIFICATION OF MISSING REQUIREMENTS UNDER 35  
U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED  
OFFICE (DO/EO/US)"

A document entitled "Sequence Listing"

Computer-readable diskette

A document entitled "Statement to Support Filing and  
Submission in Accordance with 37 C.F.R. §§ 1.821-  
1.825"

Appendix A

09/913,351

APPENDIX A

PAGE 1 OF 3

RE: U.S. Patent Application No. 09/913,351  
 Applicant: Aurora B. DELGADO, et al.  
 Title: "PHARMACOLOGICALLY ACTIVE POLYPEPTIDE  
 GLYCOCONJUGATES"  
 Our Ref.: B-4275PCT 618999-1

Please amend the fourth paragraph on page 18 of the specification  
 (see lines 14-25 on page 18) as indicated below.

Sequence: In order to comply the above conditions,  
 the polypeptides object of the present invention must  
 include in their sequence the following consensus  
 sequence (SEQ ID NO:1):

$Z_{3-48}CZ_{9-13}C(Q,E,R,K)Z(Z_{\text{hydrophobic}})(LIVM)Z_{15-39}CC(Z_{\text{hydrophilic}})$   
 $(Q,E,H)(L,V)Z_6CZCZ_2(L,I)Z_{13-56}GZ_{15-26}CZ(V,I,L,M)Z_{1-8}CZ_{1-12}$

(( )) Indicates 1 amino acid, being within the parenthesis  
 the possible ones in order of preference.  $Z_n$  indicates n  
 amino acids whichever they are. This sequence has  $CZ_nC$   
 domains (Tamaoki et al "Folding motifs induced and  
 stabilized by distinct cystine frameworks" Protein  
 engineering 11, 649-659 (1998)).

09/913,351-000001

APPENDIX APAGE 2 OF 3

RE: U.S. Patent Application No. 09/913,351  
 Applicant: Aurora B. DELGADO, et al.  
 Title: "PHARMACOLOGICALLY ACTIVE POLYPEPTIDE  
 GLYCOCONJUGATES"  
 Our Ref.: B-4275PCT 618999-1

Please amend the first paragraph on page 25 of the specification  
 (see lines 1-21 on page 25) as indicated below.

is dimeric, as determined by polyacrylamide gel electrophoresis denaturing and reducing conditions (H Schagger, G von Jagow "Tricine-sodium dodecyl sulfate polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 KDa" Anal. Biochem. 166,368-379 (1987)), the dimers being united by disulphur bridges as can be deduced from the need to use reducing conditions for the resolution by electrophoresis; it is resistant to trypsin (incubated for 24 hours at 37°C in 0.1 M Tris-HCl pH 8.5 in a polypeptide protease ratio 30:1), pepsine (incubated 24 hours at 37°C in 0.01 M HCl in a polypeptide protease ratio 25:1) and complies with the rest of the requirements described in the General Specifications of the Invention. Its sequence, determined by Edman degradation, is as follows :

Minor subunit: ESKGEREGSSSQQCRQEVQRKDLSSCERYLRQSSRR

(SEQ ID NO:2)

Major subunit:

QQQESQQLQOCCNQVKQVRDECQCEAIKYIAEDQIQGQLHGEESEVAQRAGEIVS  
 SCGVRCMRQTR (SEQ ID NO:3)

(the amino acids specified in the consensus sequence are underlined)

09913351.051301  
 F02F50.051301

APPENDIX A

PAGE 3 OF 3

RE: U.S. Patent Application No. 09/913,351  
Applicant: Aurora B. DELGADO, et al.  
Title: "PHARMACOLOGICALLY ACTIVE POLYPEPTIDE  
GLYCOCONJUGATES"  
Our Ref.: B-4275PCT 618999-1

Please amend the first paragraph on page 29 of the specification  
(see lines 1-11 on page 29) as indicated below.

hours at 37°C in 0.01M HCl in a polypeptide protease  
ratio 25:1) and complies with the rest of the  
requirements described in the General Specifications of  
the Invention. Its sequence, determined by Edman  
degradation is as follows :

Minor subunit: PSQQGCRGQIQEQQLRQCQEYIKQQVSGQGPRR (SEQ ID NO:4)

Major subunit:

QERSLRGCCDHLKQMOSQCRCEGLRQAIEQQQSOGQLQGQDVFEAFRTAANLPSMCG  
VSPTECRF (SEQ ID NO:5)

(the amino acids specified in the consensus sequence are  
underlined)

09/913,351-081301